{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T12:49:37Z","timestamp":1756385377820,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["JP16K09529"],"award-info":[{"award-number":["JP16K09529"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2020,7]]},"DOI":"10.1007\/s10067-020-04984-x","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T12:02:37Z","timestamp":1581595357000},"page":"2171-2178","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies"],"prefix":"10.1007","volume":"39","author":[{"given":"Katsuaki","family":"Asakawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Yoshizawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ami","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yosuke","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazumasa","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masachika","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Sato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5887-8375","authenticated-orcid":false,"given":"Toshinori","family":"Takada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"issue":"2","key":"4984_CR1","doi-asserted-by":"publisher","first-page":"e000507","DOI":"10.1136\/rmdopen-2017-000507","volume":"3","author":"M Bottai","year":"2017","unstructured":"Bottai M, Tjarnlund A, Santoni G, Werth VP, Pilkington C, de Visser M, Alfredsson L, Amato AA, Barohn RJ, Liang MH, Singh JA, Aggarwal R, Arnardottir S, Chinoy H, Cooper RG, Danko K, Dimachkie MM, Feldman BM, Garcia-De La Torre I, Gordon P, Hayashi T, Katz JD, Kohsaka H, Lachenbruch PA, Lang BA, Li Y, Oddis CV, Olesinka M, Reed AM, Rutkowska-Sak L, Sanner H, Selva-O'Callaghan A, Wook Song Y, Vencovsky J, Ytterberg SR, Miller FW, Rider LG, Lundberg IE, International Myositis Classification Criteria Project consortium tEr, the Juvenile Dermatomyositis Cohort Biomarker S, Repository (2017) EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report. RMD Open 3(2):e000507. https:\/\/doi.org\/10.1136\/rmdopen-2017-000507","journal-title":"RMD Open"},{"issue":"6","key":"4984_CR2","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","volume":"70","author":"LA Love","year":"1991","unstructured":"Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, Miller FW (1991) A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 70(6):360\u2013374","journal-title":"Medicine (Baltimore)"},{"issue":"6","key":"4984_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1097\/BOR.0b013e3282f01a8c","volume":"19","author":"T Mimori","year":"2007","unstructured":"Mimori T, Imura Y, Nakashima R, Yoshifuji H (2007) Autoantibodies in idiopathic inflammatory myopathy: an update on clinical and pathophysiological significance. Curr Opin Rheumatol 19(6):523\u2013529. https:\/\/doi.org\/10.1097\/BOR.0b013e3282f01a8c","journal-title":"Curr Opin Rheumatol"},{"issue":"4","key":"4984_CR4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s11926-008-0053-2","volume":"10","author":"IN Targoff","year":"2008","unstructured":"Targoff IN (2008) Autoantibodies and their significance in myositis. Curr Rheumatol Rep 10(4):333\u2013340","journal-title":"Curr Rheumatol Rep"},{"key":"4984_CR5","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/j.rmed.2017.10.020","volume":"132","author":"H Yura","year":"2017","unstructured":"Yura H, Sakamoto N, Satoh M, Ishimoto H, Hanaka T, Ito C, Hasegawa T, Tanaka S, Miyamura T, Nakashima S, Hara A, Kakugawa T, Oda K, Kido T, Obase Y, Ishimatsu Y, Yatera K, Kawakami A, Mukae H (2017) Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia. Respir Med 132:189\u2013194. https:\/\/doi.org\/10.1016\/j.rmed.2017.10.020","journal-title":"Respir Med"},{"key":"4984_CR6","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.rmed.2017.04.007","volume":"127","author":"K Tanizawa","year":"2017","unstructured":"Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Watanabe K, Aihara K, Ikezoe K, Sokai A, Nakatsuka Y, Taguchi Y, Hatta K, Noma S, Kobashi Y, Yoshizawa A, Oga T, Hirai T, Chin K, Nagai S, Izumi T, Mimori T, Mishima M (2017) The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies. Respir Med 127:57\u201364. https:\/\/doi.org\/10.1016\/j.rmed.2017.04.007","journal-title":"Respir Med"},{"key":"4984_CR7","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.rmed.2016.10.019","volume":"121","author":"H Hozumi","year":"2016","unstructured":"Hozumi H, Fujisawa T, Nakashima R, Johkoh T, Sumikawa H, Murakami A, Enomoto N, Inui N, Nakamura Y, Hosono Y, Imura Y, Mimori T, Suda T (2016) Comprehensive assessment of myositis-specific autoantibodies in polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Med 121:91\u201399. https:\/\/doi.org\/10.1016\/j.rmed.2016.10.019","journal-title":"Respir Med"},{"issue":"1","key":"4984_CR8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.resinv.2016.08.007","volume":"55","author":"N Yoshida","year":"2017","unstructured":"Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, Hoshino T (2017) Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis\/dermatomyositis-associated interstitial lung disease. Respir Investig 55(1):24\u201332. https:\/\/doi.org\/10.1016\/j.resinv.2016.08.007","journal-title":"Respir Investig"},{"issue":"16","key":"4984_CR9","doi-asserted-by":"publisher","first-page":"26552","DOI":"10.18632\/oncotarget.15716","volume":"8","author":"L Li","year":"2017","unstructured":"Li L, Wang Q, Yang F, Wu C, Chen S, Wen X, Liu C, Li Y (2017) Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. Oncotarget 8(16):26552\u201326564. https:\/\/doi.org\/10.18632\/oncotarget.15716","journal-title":"Oncotarget"},{"key":"4984_CR10","doi-asserted-by":"publisher","unstructured":"Li L, Wang Q, Wen X, Liu C, Wu C, Yang F, Zeng X, Li Y (2017) Assessment of anti-MDA5 antibody as a diagnostic biomarker in patients with dermatomyositis-associated interstitial lung disease or rapidly progressive interstitial lung disease. Oncotarget. https:\/\/doi.org\/10.18632\/oncotarget.19050","DOI":"10.18632\/oncotarget.19050"},{"key":"4984_CR11","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.rmed.2018.06.012","volume":"141","author":"T Takada","year":"2018","unstructured":"Takada T, Ohashi K, Hayashi M, Asakawa K, Sakagami T, Kikuchi T, Sato S (2018) Role of IL-15 in interstitial lung diseases in amyopathic dermatomyositis with anti-MDA-5 antibody. Respir Med 141:7\u201313. https:\/\/doi.org\/10.1016\/j.rmed.2018.06.012","journal-title":"Respir Med"},{"issue":"7","key":"4984_CR12","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.1002\/art.24621","volume":"60","author":"S Sato","year":"2009","unstructured":"Sato S, Hoshino K, Satoh T, Fujita T, Kawakami Y, Kuwana M (2009) RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60(7):2193\u20132200. https:\/\/doi.org\/10.1002\/art.24621","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4984_CR13","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1007\/s00296-008-0821-3","volume":"29","author":"M Yamagishi","year":"2009","unstructured":"Yamagishi M, Tajima S, Suetake A, Kawakami H, Watanabe T, Kuriyama H, Takada T, Suzuki E, Gejyo F (2009) Dermatomyositis with hemorrhagic myositis. Rheumatol Int 29(11):1363\u20131366. https:\/\/doi.org\/10.1007\/s00296-008-0821-3","journal-title":"Rheumatol Int"},{"issue":"4","key":"4984_CR14","doi-asserted-by":"publisher","first-page":"e00235","DOI":"10.1002\/rcr2.235","volume":"5","author":"M Hayashi","year":"2017","unstructured":"Hayashi M, Aoki A, Asakawa K, Sakagami T, Kikuchi T, Takada T (2017) Cytokine profiles of amyopathic dermatomyositis with interstitial lung diseases treated with mycophenolate. Respirol Case Rep 5(4):e00235. https:\/\/doi.org\/10.1002\/rcr2.235","journal-title":"Respirol Case Rep"},{"issue":"3","key":"4984_CR15","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s11926-011-0176-8","volume":"13","author":"E Katzap","year":"2011","unstructured":"Katzap E, Barilla-LaBarca ML, Marder G (2011) Antisynthetase syndrome. Curr Rheumatol Rep 13(3):175\u2013181. https:\/\/doi.org\/10.1007\/s11926-011-0176-8","journal-title":"Curr Rheumatol Rep"},{"issue":"3","key":"4984_CR16","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1080\/08916930600623791","volume":"39","author":"R La Corte","year":"2006","unstructured":"La Corte R, Lo Mo Naco A, Locaputo A, Dolzani F, Trotta F (2006) In patients with antisynthetase syndrome the occurrence of anti-Ro\/SSA antibodies causes a more severe interstitial lung disease. Autoimmunity 39(3):249\u2013253. https:\/\/doi.org\/10.1080\/08916930600623791","journal-title":"Autoimmunity"},{"issue":"9","key":"4984_CR17","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1007\/s00296-009-0884-9","volume":"29","author":"A Vancsa","year":"2009","unstructured":"Vancsa A, Csipo I, Nemeth J, Devenyi K, Gergely L, Danko K (2009) Characteristics of interstitial lung disease in SS-A positive\/Jo-1 positive inflammatory myopathy patients. Rheumatol Int 29(9):989\u2013994. https:\/\/doi.org\/10.1007\/s00296-009-0884-9","journal-title":"Rheumatol Int"},{"issue":"1","key":"4984_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1186\/s12931-019-1231-7","volume":"20","author":"A Sclafani","year":"2019","unstructured":"Sclafani A, D'Silva KM, Little BP, Miloslavsky EM, Locascio JJ, Sharma A, Montesi SB (2019) Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. Respir Res 20(1):256. https:\/\/doi.org\/10.1186\/s12931-019-1231-7","journal-title":"Respir Res"},{"issue":"12","key":"4984_CR19","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1136\/ard.2006.052191","volume":"65","author":"GJ Hengstman","year":"2006","unstructured":"Hengstman GJ, ter Laak HJ, Vree Egberts WT, Lundberg IE, Moutsopoulos HM, Vencovsky J, Doria A, Mosca M, van Venrooij WJ, van Engelen BG (2006) Anti-signal recognition particle autoantibodies: marker of a necrotising myopathy. Ann Rheum Dis 65(12):1635\u20131638. https:\/\/doi.org\/10.1136\/ard.2006.052191","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"4984_CR20","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/art.11484","volume":"50","author":"AH Kao","year":"2004","unstructured":"Kao AH, Lacomis D, Lucas M, Fertig N, Oddis CV (2004) Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy. Arthritis Rheum 50(1):209\u2013215. https:\/\/doi.org\/10.1002\/art.11484","journal-title":"Arthritis Rheum"},{"issue":"11","key":"4984_CR21","doi-asserted-by":"publisher","first-page":"3439","DOI":"10.1002\/art.30513","volume":"63","author":"I Marie","year":"2011","unstructured":"Marie I, Hatron PY, Dominique S, Cherin P, Mouthon L, Menard JF (2011) Short-term and long-term outcomes of interstitial lung disease in polymyositis and dermatomyositis: a series of 107 patients. Arthritis Rheum 63(11):3439\u20133447. https:\/\/doi.org\/10.1002\/art.30513","journal-title":"Arthritis Rheum"},{"issue":"8","key":"4984_CR22","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s00296-017-3729-y","volume":"37","author":"K Isoda","year":"2017","unstructured":"Isoda K, Kotani T, Takeuchi T, Kiboshi T, Hata K, Ishida T, Otani K, Kamimori T, Fujiwara H, Shoda T, Makino S (2017) Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody. Rheumatol Int 37(8):1335\u20131340. https:\/\/doi.org\/10.1007\/s00296-017-3729-y","journal-title":"Rheumatol Int"},{"key":"4984_CR23","doi-asserted-by":"publisher","first-page":"815245","DOI":"10.1155\/2014\/815245","volume":"2014","author":"H Kawasumi","year":"2014","unstructured":"Kawasumi H, Gono T, Kawaguchi Y, Kaneko H, Katsumata Y, Hanaoka M, Kataoka S, Yamanaka H (2014) IL-6, IL-8, and IL-10 are associated with hyperferritinemia in rapidly progressive interstitial lung disease with polymyositis\/dermatomyositis. Biomed Res Int 2014:815245. https:\/\/doi.org\/10.1155\/2014\/815245","journal-title":"Biomed Res Int"},{"key":"4984_CR24","doi-asserted-by":"publisher","unstructured":"Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H (2014) Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keu258","DOI":"10.1093\/rheumatology\/keu258"},{"issue":"4","key":"4984_CR25","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1084\/jem.166.4.1084","volume":"166","author":"AD Luster","year":"1987","unstructured":"Luster AD, Ravetch JV (1987) Biochemical characterization of a gamma interferon-inducible cytokine (IP-10). J Exp Med 166(4):1084\u20131097","journal-title":"J Exp Med"},{"issue":"5","key":"4984_CR26","doi-asserted-by":"publisher","first-page":"2722","DOI":"10.4049\/jimmunol.179.5.2722","volume":"179","author":"NK Dhillon","year":"2007","unstructured":"Dhillon NK, Peng F, Ransohoff RM, Buch S (2007) PDGF synergistically enhances IFN-gamma-induced expression of CXCL10 in blood-derived macrophages: implications for HIV dementia. J Immunol 179(5):2722\u20132730","journal-title":"J Immunol"},{"issue":"3","key":"4984_CR27","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1359-6101(97)00015-4","volume":"8","author":"LF Neville","year":"1997","unstructured":"Neville LF, Mathiak G, Bagasra O (1997) The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 8(3):207\u2013219","journal-title":"Cytokine Growth Factor Rev"},{"issue":"5","key":"4984_CR28","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.autrev.2008.12.002","volume":"8","author":"EY Lee","year":"2009","unstructured":"Lee EY, Lee ZH, Song YW (2009) CXCL10 and autoimmune diseases. Autoimmun Rev 8(5):379\u2013383. https:\/\/doi.org\/10.1016\/j.autrev.2008.12.002","journal-title":"Autoimmun Rev"},{"issue":"3","key":"4984_CR29","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1016\/j.autrev.2013.10.010","volume":"13","author":"A Antonelli","year":"2014","unstructured":"Antonelli A, Ferrari SM, Giuggioli D, Ferrannini E, Ferri C, Fallahi P (2014) Chemokine (C-X-C motif) ligand (CXCL)10 in autoimmune diseases. Autoimmun Rev 13(3):272\u2013280. https:\/\/doi.org\/10.1016\/j.autrev.2013.10.010","journal-title":"Autoimmun Rev"},{"issue":"6","key":"4984_CR30","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1007\/s10753-019-01073-3","volume":"42","author":"S Kawaguchi","year":"2019","unstructured":"Kawaguchi S, Sakuraba H, Haga T, Matsumiya T, Seya K, Endo T, Sawada N, Iino C, Kikuchi H, Hiraga H, Fukuda S, Imaizumi T (2019) Melanoma differentiation-associated gene 5 positively modulates TNF-alpha-induced CXCL10 expression in cultured HuH-7 and HLE cells. Inflammation 42(6):2095\u20132104. https:\/\/doi.org\/10.1007\/s10753-019-01073-3","journal-title":"Inflammation"},{"issue":"1\u20132","key":"4984_CR31","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, Ytterberg SR, Gregersen PK, Behrens TW, Reed AM (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Molecular medicine (Cambridge, Mass) 13(1\u20132):59\u201368. https:\/\/doi.org\/10.2119\/2006-00085.Baechler","journal-title":"Molecular medicine (Cambridge, Mass)"},{"issue":"11","key":"4984_CR32","doi-asserted-by":"publisher","first-page":"3436","DOI":"10.1002\/art.24936","volume":"60","author":"H Bilgic","year":"2009","unstructured":"Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, Ellingson S, Newman B, Bauer JW, Peterson EJ, Baechler EC, Reed AM (2009) Interleukin-6 and type I interferon-regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 60(11):3436\u20133446. https:\/\/doi.org\/10.1002\/art.24936","journal-title":"Arthritis Rheum"},{"issue":"12","key":"4984_CR33","doi-asserted-by":"publisher","first-page":"4078","DOI":"10.1002\/art.34659","volume":"64","author":"AM Reed","year":"2012","unstructured":"Reed AM, Peterson E, Bilgic H, Ytterberg SR, Amin S, Hein MS, Crowson CS, Ernste F, Gillespie EB (2012) Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course. Arthritis Rheum 64(12):4078\u20134086. https:\/\/doi.org\/10.1002\/art.34659","journal-title":"Arthritis Rheum"},{"issue":"5","key":"4984_CR34","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1111\/bjd.15006","volume":"176","author":"C Huard","year":"2017","unstructured":"Huard C, Gulla SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA (2017) Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon beta in dermatomyositis. Br J Dermatol 176(5):1224\u20131230. https:\/\/doi.org\/10.1111\/bjd.15006","journal-title":"Br J Dermatol"},{"issue":"1","key":"4984_CR35","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1038\/s41598-017-01685-5","volume":"7","author":"K Oda","year":"2017","unstructured":"Oda K, Kotani T, Takeuchi T, Ishida T, Shoda T, Isoda K, Yoshida S, Nishimura Y, Makino S (2017) Chemokine profiles of interstitial pneumonia in patients with dermatomyositis: a case control study. Sci Rep 7(1):1635. https:\/\/doi.org\/10.1038\/s41598-017-01685-5","journal-title":"Sci Rep"},{"key":"4984_CR36","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.intimp.2019.02.039","volume":"70","author":"X Gui","year":"2019","unstructured":"Gui X, Qiu X, Tian Y, Xie M, Li H, Gao Y, Zhuang Y, Cao M, Ding H, Ding J, Zhang Y, Cai H (2019) Prognostic value of IFN-gamma, sCD163, CCL2 and CXCL10 involved in acute exacerbation of idiopathic pulmonary fibrosis. Int Immunopharmacol 70:208\u2013215. https:\/\/doi.org\/10.1016\/j.intimp.2019.02.039","journal-title":"Int Immunopharmacol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-020-04984-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-020-04984-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,12]],"date-time":"2021-02-12T00:28:32Z","timestamp":1613089712000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-020-04984-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2020,7]]}},"alternative-id":["4984"],"URL":"https:\/\/doi.org\/10.1007\/s10067-020-04984-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"assertion":[{"value":"29 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}